PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 174-179

  Park, Jun Beom ^a   Kwon, Young Min ^a,b   Lee, Tien Yi ^a   Brim, Remy ^c   Ko, Mei Chuan ^c   Sunahara, Roger K ^c   Woods, James H ^c   Yang, Victor C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cocaine esterase; Immunogenicity; PEGylation; Protease digestion

Indexed keywords

CLINICAL APPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; IN-VIVO; NATIVE ENZYMES; NATURALLY OCCURRING; PEGYLATION; PROTEASE DIGESTION; RAPID DEGRADATION; THERMAL DEGRADATIONS; THERMO-INSTABILITY; TOXIC EFFECT;

ANIMALS; DEGRADATION; ENZYMES; POLYETHYLENE OXIDES;

POLYETHYLENE GLYCOLS;

CARBOXYLESTERASE; COCAINE; MACROGOL; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; ENZYME DEGRADATION; IMMUNOGENICITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; COCAINE; COCAINE-RELATED DISORDERS; ENZYME STABILITY; MALE; MICE; POLYETHYLENE GLYCOLS; RHODOCOCCUS; TEMPERATURE; TRYPSIN;

EID: 76749083724     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.015     Document Type: Article

References (31)

1. Ascenzi P., Clementi E., Polticelli F. The Rhodococcus sp. cocaine esterase: a bacterial candidate for novel pharmacokinetic-based therapies for cocaine abuse. IUBMB Life 2003, 55(7):397-402.
2. Rogers C.J., Mee J.M., Kaufmann G.F., Dickerson T.J., Janda K.D. Toward cocaine esterase therapeutics. J. Am. Chem. Soc. 2005, 127(28):10016-10017.
3. Larsen N.A., Turner J.M., Stevens J., Rosser S.J., Basran A., Lerner R.A., Bruce N.C., Wilson I.A. Crystal structure of a bacterial cocaine esterase. Nat. Struct. Biol. 2002, 9(1):17-21.
4. Ko M.C., Bowen L.D., Narasimhan D., Berlin A.A., Lukacs N.W., Sunahara R.K., Cooper Z.D., Woods J.H. Cocaine esterase: interactions with cocaine and immune responses in mice. J. Pharmacol. Exp. Ther. 2007, 320(2):926-933.
5. Gao D., Narasimhan D.L., Macdonald J., Brim R., Ko M.C., Landry D.W., Woods J.H., Sunahara R.K., Zhan C.G. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 2009, 75(2):318-323.
6. Cooper Z.D., Narasimhan D., Sunahara R.K., Mierzejewski P., Jutkiewicz E.M., Larsen N.A., Wilson I.A., Landry D.W., Woods J.H. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 2006, 70(6):1885-1891.
7. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 2003, 55(10):1261-1277.
8. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 2006, 116(2):123-129.
9. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 2003, 55(10):1293-1302.
10. Kozlowski A., Harris J.M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 2001, 72(1-3):217-224.
11. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 2001, 12(2):195-202.
12. Wroblewski J.J., Wells J.A., Adamis A.P., Buggage R.R., Cunningham E.T., Goldbaum M., Guyer D.R., Katz B., Altaweel M.M. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch. Ophthalmol. 2009, 127(4):374-380.
13. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 22(2):143-152. Eyetech_Study_Group.
14. Turner J.M., Larsen N.A., Basran A., Barbas C.F., Bruce N.C., Wilson I.A., Lerner R.A. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 2002, 41(41):12297-12307.
15. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10(21):1451-1458.
16. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22(5):405-417.
17. Wang J.H., Tam S.C., Huang H., Ouyang D.Y., Wang Y.Y., Zheng Y.T. Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro. Biochem. Biophys. Res. Commun. 2004, 317(4):965-971.
18. Li W., Wang Y., Zhu X., Li M., Su Z. Preparation and characterization of PEGylated adducts of recombinant human tumor necrosis factor-alpha from Escherichia coli. J. Biotechnol. 2002, 92(3):251-258.
19. Ramon J., Saez V., Baez R., Aldana R., Hardy E. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm. Res. 2005, 22(8):1374-1386.
20. Rodriguez-Martinez J.A., Rivera-Rivera I., Sola R.J., Griebenow K. Enzymatic activity and thermal stability of PEG-alpha-chymotrypsin conjugates. Biotechnol. Lett. 2009, 31(6):883-887.
21. Rodriguez-Martinez J.A., Sola R.J., Castillo B., Cintron-Colon H.R., Rivera-Rivera I., Barletta G., Griebenow K. Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol. Bioeng. 2008, 101(6):1142-1149.
22. Greenwald R.B. PEG drugs: an overview. J. Control. Release 2001, 74(1-3):159-171.
23. Choe Y.H., Conover C.D., Wu D., Royzen M., Gervacio Y., Borowski V., Mehlig M., Greenwald R.B. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control. Release 2002, 79(1-3):55-70.
24. Lee H., Jang I.H., Ryu S.H., Park T.G. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 2003, 20(5):818-825.
25. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control. Release 2008, 127(3):239-248.
26. Ko M.C., Narasimhan D., Berlin A.A., Lukacs N.W., Sunahara R.K., Woods J.H. Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend. 2009, 101(3):202-209.
27. Takagi A., Yamashita N., Yoshioka T., Takaishi Y., Sano K., Yamaguchi H., Maeda A., Saito K., Takakura Y., Hashida M. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J. Control. Release 2007, 119(3):271-278.
28. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J. Control. Release 2008, 125(1):68-75.
29. Cox G.N., Rosendahl M.S., Chlipala E.A., Smith D.J., Carlson S.J., Doherty D.H. A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Endocrinology 2007, 148(4):1590-1597.
30. Clark R., Olson K., Fuh G., Marian M., Mortensen D., Teshima G., Chang S., Chu H., Mukku V., Canova-Davis E., Somers T., Cronin M., Winkler M., Wells J.A. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 1996, 271(36):21969-21977.
31. He X.H., Shaw P.C., Tam S.C. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999, 65(4):355-368.